Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Sindrome de Raymont
Sindrome de Raymont
Introducción
Epidemiología
Clasificación
Fisiopatología
Clínica
REVISIÓN
DOI: 10.1016/S1699-258X(08)71801-1
Acceso a texto completo
Introducción
Epidemiología
Clasificación
Tabla 1.
FR primario FR secundario
Asociación con
enfermedad No Sí
Edad de aparición < 30 años > 30 años
Úlceras/necrosis Raro, leve Frecuente
Dilataciones capilares /zonas sin
Capilaroscopia Normal capilares /hemorragias
Negativos o títulos
Autoanticuerpos bajos Frecuentes
Fisiopatología
SNS, se cree que los factores más influyentes son los locales,
dependientes o no del endotelio vascular.
El frío o el estrés causan una activación del SNS, que actúa sobre los
receptores a2-adrenérgicos del músculo liso de los vasos periféricos,
produciendo su vasoconstricción. La actividad de estos receptores a2-
adrenérgicos está aumentada en los pacientes con FR, sin necesidad de
que haya ninguna disfunción endotelial . Se piensa que éste es el
13
Diagnóstico
-
-
-
Tratamiento
Medidas generales
Vasodilatadores
Terapia antiagregante/anticoagulante
Terapia antioxidante
Cirugía
Debe ser considerada una urgencia médica, por lo que suele ser
necesario el ingreso hospitalario. Como medidas generales se debe
recomendar reposo, procurar una adecuada temperatura ambiental y
control del dolor, si es preciso con infiltraciones locales de
anestésicos. Asimismo es imprescindible evitar infecciones, mediante
curas oclusivas antisépticas acompañadas o no de antibioterapia
general y con desbridamiento quirúrgico cuando es necesario. Como
terapia vasodilatadora generalmente se opta por prostaciclinas
intravenosas (iloprost 0,5-2ng/kg/min durante 1–3 días). Aunque
como ya se ha comentado previamente, este punto no está claro,
algunos pacientes podrían beneficiarse de anticoagulación con
heparina sódica o con heparinas de bajo peso molecular durante 24–
72h. Finalmente si estas medidas no resultaran eficaces, puede
plantearse tratamiento quirúrgico con simpatectomía proximal o
digital según los casos .
55
Bibliografía
[1.]
F.M. Wigley.
Raynaud’s phenomenon.
N Engl J Med, 347 (2002), pp. 1001-1008
http://dx.doi.org/10.1056/NEJMcp013013 | Medline
[2.]
F.M. Wigley.
Raynaud’s phenomenon.
Curr Opin Rheumatol, 5 (1993), pp. 773-784
Medline
[3.]
H.R. Maricq, P.H. Carpentier, M.C. Weinrich, J.E. Keil, Y. Palesch,
C. Biro, et al.
Geographic variation in the prevalence of Raynaud’s
phenomenon: a 5 region comparison.
J Rheumatol, 24 (1997), pp. 879-889
Medline
[4.]
H.R. Maricq, M.C. Weinrich, J.E. Keil, E.C. LeRoy.
Prevalence of Raynaud phenomenon in the general population. A
preliminary study by questionnaire.
J Chronic Dis, 39 (1986), pp. 423-427
Medline
[5.]
N. Olsen, S.L. Neilsen.
Prevalence of primary Raynaud’s phenomenon in young females.
Scand J Clin Lab Invest, 37 (1978), pp. 761-764
[6.]
L. Fraenkel, Y. Zhang, C.E. Chaisson, H.R. Maricq, S.R. Evans, F.
Brand, et al.
Different factors influencing the expression of Raynaud’s
phenomenon in men and women.
Arthritis Rheum, 42 (1999), pp. 306-310
http://dx.doi.org/10.1002/1529-0131(199902)42:2<306::AID-
ANR13>3.0.CO;2-G | Medline
[7.]
Y.Y. Palesch, I. Valter, P.H. Carpentier, H.R. Maricq.
Association between cigarette and alcohol consumption and
Raynaud’s phenomenon.
J Clin Epidemiol, 52 (1999), pp. 321-328
Medline
[8.]
F.K. Tan, F.C. Arnett.
Genetics factors in the etiology of systemic sclerosis and
Raynaud’s phenomenon.
Curr Opin Rheumatol, 12 (2000), pp. 511-519
Medline
[9.]
D.D. Gerbracht, V.D. Steen, G.L. Ziegler, T.A. Medsger, G.P.
Rodnan.
Evolution of primary Raynaud’ phenomenon (Raynaud’s disease)
to connective tissue disease.
Arthritis Rheum, 28 (1985), pp. 87-92
Medline
[10.]
G.J. Landry, J.M. Edwards, R.B. McLafferty, L.M. Taylor Jr, J.M.
Porter.
Long-term outcome of Raynaud’s syndrome in a prospectively
analyzed patient cohort.
J Vasc Surg, 23 (1996), pp. 76-78
Medline
[11.]
G. Spencer-Green.
Outcomes in primary Raynaud phenomenon: a metaanalysis of
the frequency, rates and predictors of transition to secondary
disease.
Arch Intern Med, 158 (1998), pp. 595-600
Medline
[12.]
T. Lewis.
Experiments relating to the peripheral mechanism involved in
spasmodic arrest of the circulation of the fingers: a variety of
Raynaud’s disease.
Heart, 14 (1929), pp. 7-101
[13.]
N.A. Flavahan, S. Flavahan, Q. Liu, S. Wu, W. Tidmore, C.M.
Wiener, et al.
Increased alpha2-adrenergic constriction of isolated arterioles in
diffuse scleroderma.
Arthritis Rheum, 43 (2000), pp. 1886-1890
http://dx.doi.org/10.1002/1529-0131(200008)43:8<1886::AID-
ANR27>3.0.CO;2-S | Medline
[14.]
J. Block, W. Sequeira.
Raynaud’s phenomenon.
Lancet, 357 (2001), pp. 2042-2048
http://dx.doi.org/10.1016/S0140-6736(00)05118-7 | Medline
[15.]
F.M. Wigley, N.A. Flavahan.
Raynaud’s phenomenon.
Rheum Dis Clin North Am, 22 (1996), pp. 765-781
Medline
[16.]
M.B. Kahaleh, P.S. Fan.
Mechanism of serum-mediated endothelial injury in scleroderma:
identification of a granular enzyme in scleroderma skin and sera.
Clin Immunol Immunopathol, 83 (1997), pp. 32-40
Medline
[17.]
R. Sgonc, M.S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, G. Wick.
Endothelial cell apoptosis in systemic sclerosis is induced by
antibody-dependent cell-mediated cytotoxicity via CD95.
Arthritis Rheum, 43 (2000), pp. 2550-2562
http://dx.doi.org/10.1002/1529-0131(200011)43:11<2550::AID-
ANR24>3.0.CO;2-H | Medline
[18.]
C.B. Bunker, G. Teranghi, D.R. Springall, J.M. Polak, P.M. Dowd.
Deficiency of calcitonin gene-related peptide in Raynaud’s
phenomenon.
Lancet, 336 (1990), pp. 1530-1533
Medline
[19.]
N.A. Flavahan, S. Flavahan, S. Mitra, M.A. Chotani.
The vasculopathy of Raynaud’s phenomenon and scleroderma.
Rheum Dis Clin North Am, 29 (2003), pp. 275-291
Medline
[20.]
L.K. Hummers, F.M. Wigley.
Management of Raynaud’s phenomenon and digital ischemic
lesions in scleroderma.
Rheum Dis Clin North Am, 29 (2003), pp. 293-313
Medline
[21.]
G.P. Rodnan, R.L. Myerowitz, G.O. Justh.
Morphologic changes in the digital arteries of patients with
progressive systemic sclerosis (scleroderma) and Raynaud’s
phenomenon.
Medicine (Baltimore), 59 (1980), pp. 393-408
[22.]
Z. Mackiewicz, A. Sukura, D. Povilenaité, A. Ceponis, I. Virtanen, M.
Hukkanen, et al.
Increased but imbalanced expression of VEGF and its receptors
has no positive effect on angiogenesis in systemic sclerosis skin.
Clin Exp Rheumatol, 20 (2002), pp. 641-646
Medline
[23.]
Y.T. Konttinen, Z. Mackiewicz, P. Ruutttila, A. Ceponis, A. Sukura,
D. Povilenaité, et al.
Vascular damage and lack of angiogenesis in systemic sclerosis
skin.
Clin Rheumatol, 22 (2003), pp. 196-202
http://dx.doi.org/10.1007/s10067-003-0698-1 | Medline
[24.]
R.F. Macko, A.C. Gelber, B.A. Young, M.H. Lowitt, B. White, F.M.
Wigley, et al.
Increased circulating concentrations of the counter adhesive
proteins sparc and thrombospondin-1 in systemic sclerosis
(scleroderma). Relationship to platelet and endothelial cell
activation.
J Rheumatol, 29 (2002), pp. 2565-2570
Medline
[25.]
P.A. Merkel, K. Herlyn, R.W. Martin, J.J. Anderson, M.D. Mayes, P.
Bell, et al.
Scleroderma Clinical Trials Consortium Measuring disease
activity and functional status in patients with scleroderma and
Raynaud’s phenomenon.
Arthritis Rheum, 46 (2002), pp. 2410-2420
http://dx.doi.org/10.1002/art.10486 | Medline
[26.]
Comparison of sustained-release nifedipine and temperature
biofeedback for treatment of primary Raynaud’s phenomenon.
Results from randomized clinical trial with 1-year follow-up.
Arch Intern Med, 160 (2000), pp. 1101-1108
Medline
[27.]
L. Fraenkel.
Raynaud’s phenomenon: epidemiology and risk factors.
Curr Rheumatol Rep, 4 (2002), pp. 123-128
Medline
[28.]
B.J. Harrison, A.J. Silman, S. Hider, A.L. Herrick.
Cigarette smoking: a risk factor for digital vascular complications
in systemic sclerosis.
Arthritis Rheum, 4 (2002), pp. 3312-3316
[29.]
L. Fraenkel, Y. Zhang, C.E. Chaisson, S.R. Evans, P.W. Wilson, D.T.
Felson.
The association of estrogen replacement therapy and the Raynaud
phenomenon in postmenopausal women.
Ann Intern Med, 129 (1998), pp. 208-211
Medline
[30.]
J. Lekakis, C. Papamichel, M. Mavrikakis, A. Voutsas, S.
Stamatelopoulos.
Effect of long-term estrogen therapy on brachial arterial
endothelium-dependent vasodilation in women with Raynaud’s
phenomenon secondary to systemic sclerosis.
Am J Cardiol, 82 (1998), pp. 1555-1557
Medline
[31.]
L.H. Opie.
Pharmacological differences between calcium antagonists.
Eur Heart J, 18 (1997), pp. A71-A79
Medline
[32.]
A.E. Thompson, B. Shea, V. Welch, D. Fenlon, J.E. Pope.
Calcium-channel blockers for Raynaud’s phenomenon in systemic
sclerosis.
Arthritis Rheum, 44 (2001), pp. 1841-1847
http://dx.doi.org/10.1002/1529-0131(200108)44:8<1841::AID-
ART322>3.0.CO;2-8 | Medline
[33.]
M. Rademaker, E.D. Cooke, N.E. Almond, J.A. Beacham, R.E. Smith,
T.G. Mant, et al.
Comparison of intravenous infusions of iloprost and oral
nifedipine in treatment of Raynaud’s phenomenon in patients
with systemic sclerosis: a double blind randomized study.
Bmj, 298 (1989), pp. 561-564
Medline
[34.]
A.E. Thompson, J.E. Pope.
Calcium-channel blockers for Raynaud’s phenomenon: a meta-
analysis.
Rheumatology (Oxford), 44 (2005), pp. 145-150
[35.]
L. La Civita, N. Pitaro, M. Rossi, I. Gambini, D. Giuggioli, G. Cini, et
al.
Amlodipine in the treatment of Raynaud’s phenomenon.
Br J Rheumatol, 32 (1993), pp. 524-525
Medline
[36.]
C.G. Kallenberg, A.A. Wouda, L. Meems, H. Wesseling.
Once daily felodipine in patients with primary Raynaud’s
phenomenon.
Eur J Clin Pharmacol, 40 (1991), pp. 313-315
Medline
[37.]
J.F. Schmidt, N. Valentin, S.L. Nielsen.
The clinical effect of felodipine and nifedipine in Raynaud’s
phenomenon.
Eur J Clin Pharmacol, 37 (1989), pp. 191-192
Medline
[38.]
J. Leppert, T. Jonasson, H. Nilsson, I. Ringqvist.
The effect of isradipine, a new calcium-channel antagonist, in
patients with primary Raynaud’s phenomenon: a single-blind
dose response study.
Cardiovasc Drugs Ther, 3 (1989), pp. 397-401
Medline
[39.]
M.G. Sturgill, J.R. Seibold.
Rational use of calcium-channel antagonists in Raynaud’s
phenomenon.
Curr Op Rheumatol, 10 (1998), pp. 584-588
[40.]
H. Wollersheim, T. Thien.
Double-blind placebo controlled crossover study of oral
nicardipine in the treatment of Raynaud’s phenomenon.
J Cardiovasc Pharmacol, 18 (1991), pp. 813-818
Medline
[41.]
J. Da Costa, J.A. Gomes, J. Espirito Santo, M. Queirós.
Inefficacy of diltiazem in the treatment of Raynaud’s phenomenon
with associated connective tissue disease: a double blind placebo
controlled study.
J Rheumatol, 14 (1987), pp. 858-859
Medline
[42.]
E.L. Kinney, G.G. Nicholas, J. Gallo, C. Pontoriero, R. Zelis.
The treatment of severe Raynaud’s phenomenon with verapamil.
J Clin Pharmacol, 22 (1982), pp. 74-76
Medline
[43.]
M. Mittag, P. Beckheinrich, U.F. Haustein.
Systemic sclerosis-related Raynaud’s phenomenon: effects of
iloprost infusion therapy on serum cytokine, growth factor and
soluble adhesion molecule levels.
Acta Derm Venereol, 81 (2001), pp. 294-297
Medline
[44.]
M.B. Kahaleh, M. Matucci Cerinic, P.-S. Fan.
Modulation of endothelial gene expression by prostanoids in
systemic sclerosis.
Arthritis Rheum, 43 (2000), pp. S258
[45.]
J.S. Mohrland, J.M. Porter, E.A. Smith, J. Belch, M.H. Simms.
A multiclinic, placebo-controlled, double-blind study of
prostaglandin E1 in Raynaud’s syndrome.
Ann Rheum Dis, 44 (1985), pp. 754-760
Medline
[46.]
P. Lamprecht, A. Schnabel, W.L. Gross.
Efficacy of alprostail and iloprost in digital necrosis due to
secondary Raynaud’s phenomenon.
Br J Rheumatol, 37 (1998), pp. 703-704
Medline
[47.]
B. Marasini, M. Massarottti, B. Bottasso, R. Coppola, N. Del Papa, W.
Maglione, et al.
Comparison between iloprost and alprostadil in the treatment of
Raynaud’s phenomenon.
Scan J Rheumatol, 33 (2004), pp. 253-256
[48.]
J.J. Belch, P. Newman, J.K. Drury, H. Capell, P. Leiberman, W.B.
James, et al.
Successful treatment of Raynaud’s syndrome with prostacyclin.
Thromb Haemost, 45 (1981), pp. 255-256
Medline
[49.]
P.M. Dowd, M.F.R. Martin, E.D. Cooke, S.A. Bow-Cock, R. Jones,
P.A. Ieppe, et al.
Treatment of Raynaud’s phenomenon by intravenous infusion of
prostacyclin (PGI2).
Br J Dermatol, 106 (1982), pp. 81-89
Medline
[50.]
J.J. Belch, J.K. Drury, H. Capell, C.D. Forbes, P. Newman, F.
McKenzie, et al.
Intermittent epoprostenol (prostacyclin) infusion in patients with
Raynaud’s syndrome. A double-blind controlled trial.
Lancet, 1 (1983), pp. 313-315
Medline
[51.]
N.J. McHugh, M. Csuka, H. Watson, G. Belcher, A. Amadi, E.F.
Ring, et al.
Infusion of iloprost, a prostacyclin analogue, for treatment of
Raynaud’s phenomenon in systemic sclerosis.
Ann Rheum Dis, 47 (1988), pp. 43-47
Medline
[52.]
D.A. Yardumian, D.A. Isenberg, M. Rustin, G. Belcher, M.L. Snaith,
P.M. Dowd, et al.
Successful treatment of Raynaud’s syndrome with Iloprost, a
chemically stable prostacyclin analogue.
Br J Rheumtol, 27 (1988), pp. 220-226
[53.]
M.V. Kyle, G. Belcher, B.L. Hazleman.
Placebo controlled study showing therapeutic benefit of iloprost in
the treatment of Raynaud’s phenomenon.
J Rheumatol, 19 (1992), pp. 1403-1406
Medline
[54.]
F.M. Wigley, J.R. Seibold, R.A. Wise, D.A. McCloskey, W.P. Dole.
Intravenous iloprost treatment of Raynaud’s phenomenon and
ischemic ulcers secondary to systemic sclerosis.
J Rheumatol, 19 (1992), pp. 1407-1414
Medline
[55.]
F.M. Wigley, R.A. Wise, J.R. Seibold, D.A. McCloskey, G. Kujala,
T.A. Medsger, et al.
Intravenous iloprost infusion in patients with Raynaud’s
phenomenon secondary to systemic sclerosis. A multicenter,
placebo-controlled, double-blind study.
Ann Int Med, 120 (1994), pp. 199-206
Medline
[56.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Iloprost and cicaprost for Raynaud’s phenomenon in progressive
systemic sclerosis.
Cochrane Database Sys Rev, 1 (2005),
[57.]
J.J. Belch, H.A. Capell, E.D. Cooke, J.D. Kirby, C.S. Lau, R.
Madhok, et al.
Oral iloprost as a treatment for Raynaud’s syndrome: a double-
blind, multicentre, placebo controlled study.
Ann Rheum Dis, 54 (1995), pp. 197-200
Medline
[58.]
C.S. Lau, J.J. Belch, R. Madhok, H. Cappell, A. Herrick, M.
Jayson, et al.
A randomized, double-blind study of cicaprost, an oral
prostacyclin analogue, in the treatment of Raynaud’s
phenomenon secondary to systemic sclerosis.
Clin Exp Rheumatol, 11 (1993), pp. 35-40
Medline
[59.]
F.M. Wigley, J.H. Korn, M.E. Csuka, T.A. Medsger Jr, N.F.
Rothfield, M. Ellman, et al.
Oral iloprost treatment in patients with Raynaud’s phenomenon
secondary to systemic sclerosis. A multicentre, placebo-controlled,
doubleblind study.
Arthritis Rheum, 41 (1998), pp. 670-677
http://dx.doi.org/10.1002/1529-0131(199804)41:4<670::AID-
ART14>3.0.CO;2-I | Medline
[60.]
C.M. Black, L. Halkier Sorensen, J.J.F. Belch, S. Ullman, R. Madhik,
A.J. Smith, et al.
Oral iloprost in Raynaud’s phenomenon secondary to systemic
sclerosis: a multicentre, placebo-controlled, dose-comparison
study.
Br J Rheumatol, 37 (1998), pp. 952-960
Medline
[61.]
R.A. Wise, F. Wigley.
Acute effects of misoprostol on digital circulation in patients with
Raynaud’s phenomenon.
J Rheumatol, 21 (1994), pp. 80-83
Medline
[62.]
M. Vayssairat.
Controlled multicenter double blind trial of an oral analog of
prostacyclin in the treatment of primary Raynaud’s phenomenon.
French Microcirculation Society Multicentre Group for the Study
of Vascular Acrosyndromes.
J Rheumatol, 23 (1996), pp. 1917-1920
Medline
[63.]
M. Rademaker, E.D. Cooke, N.E. Almond, J.A. Beacham, R.E. Smith,
T.G. Mant, et al.
Comparison of intravenous infusions of iloprost and oral
nifedipine in treatment of Raynaud’s phenomenon in patients
with systemic sclerosis: a double blind randomized study.
BMJ, 298 (1989), pp. 561-564
Medline
[64.]
R. Scorza, M. Caronni, B. Mascagni, V. Berruti, S. Bazzi, E.
Micallef, et al.
Effects of long-term cyclic iloprost therapy in systemic sclerosis
with Raynaud’s phenomenon. A randomized, controlled study.
Clin Exp Rheumatol, 19 (2001), pp. 503-508
Medline
[65.]
P. Maddison.
Prevention of vascular damage in scleroderma with angiotensin-
converting enzyme (ACE) inhibition.
Rheumatology (Oxford), 41 (2002), pp. 965-971
[66.]
M. Dziadzio, C.P. Denton, R. Smith, K. Howell, A. Blann, E.
Bowers, et al.
Losartan therapy for Raynaud’s phenomenon and scleroderma:
clinical and biochemical findings in a fifteen-week, randomized,
parallel-group, controlled trial.
Arthritis Rheum, 42 (1999), pp. 2646-2655
http://dx.doi.org/10.1002/1529-0131(199912)42:12<2646::AID-
ANR21>3.0.CO;2-T | Medline
[67.]
I.J. Russell, J.A. Lessard.
Prazosin treatment of Raynaud’s phenomenon: a double blind
single crossover study.
J Rheumatol, 12 (1985), pp. 94-98
Medline
[68.]
R.S. Surwit, R.S. Gilgor, L.M. Allen, M. Duvic.
A double-blind study of prazosin in the treatment of Raynaud’s
phenomenon in scleroderma.
Arch Dermatol, 120 (1984), pp. 329-331
Medline
[69.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Prazosin for Raynaud’s phenomenon in progressive systemic
sclerosis.
Cochrane Database Sys Rev, 1 (2005),
[70.]
R.A. Wise, F.M. Wigley, B. White, G. Leatherman, J. Zhong, H.
Krasa, et al.
Efficacy and tolerability of a selective alpha(2C)-adrenergic
receptor blocker in recovery from cold-induced vasospasm in
scleroderma patients: a single-center, double-blind, placebo-
controlled, randomized crossover study.
Arthritis Rheum, 50 (2004), pp. 3994-4001
http://dx.doi.org/10.1002/art.20665 | Medline
[71.]
M.E. Anderson, T.L. Moore, S. Hollis, M.I. Jayson, T.A. King, A.L.
Herrick.
Digital vascular response to topical glyceryl trinitrate, as
measured by laser Doppler imaging, in primary Raynaud’s
phenomenon and systemic sclerosis.
Rheumatology (Oxford), 41 (2002), pp. 324-328
[72.]
C. Kan, S. Akimoto, M. Abe, K. Okada, O. Ishikawa.
Preliminary thermographic evaluation of new nitroglycerine tape
on the peripheral circulatory disturbance in systemic sclerosis.
Ann Rheum Dis, 61 (2002), pp. 177-179
Medline
[73.]
R.R. Freedman, R. Girgis, M.D. Mayes.
Acute effect of nitric oxide on Raynaud’s phenomenon in
scleroderma.
Lancet, 354 (1999), pp. 739
http://dx.doi.org/10.1016/S0140-6736(99)01862-0 | Medline
[74.]
C.M. Rembold, C.R. Ayers.
Oral L-arginine can reverse digital necrosis in Raynaud’s
phenomenon.
Mol Cell Biochemi, 244 (2003), pp. 139-141
[75.]
B.K.S. Sastry, C. Narasimhan, N. Krishna Reddy, B. Soma Raju.
Clinical efficacy of sildenafil in primary pulmonary hypertension.
A randomized, placebo-controlled, double-blind, crossover study.
J Am Coll Cardiol, 43 (2004), pp. 1149-1153
http://dx.doi.org/10.1016/j.jacc.2003.10.056 | Medline
[76.]
G. Simonneau, G. Burgess, T. Parpia, D. Badesch.
Sildenafil improves exercise ability and hemodynamics in patients
with pulmonary arterial hypertension associated with connective
tissue disease.
Ann Rheum Dis, 64 (2005), pp. 109.
http://dx.doi.org/10.1136/ard.2004.029280 | Medline
[77.]
S. Rosenkranz, F. Diet, T. Karasch, J. Weinbrauc, K. Wasserman, E.
Erdman.
Sildenafil improved pulmonary hypertension and peripheral
blood flow in patient with scleroderma-associated lung fibrosis
and Raynaud phenomenon.
Ann Int Med, 139 (2003), pp. 871-872
Medline
[78.]
J. Gore, R. Silver.
Oral sildenafil for the treatment of Raynaud’s phenomenon and
digital ulcers secondary to systemic sclerosis.
Ann Rheum Dis, 64 (2005), pp. 1387
http://dx.doi.org/10.1136/ard.2004.034488 | Medline
[79.]
M. Baumhaekel, P. Scheffler, M. Boehm.
Use of tadalafil in a patient with secondary Raynaud’s
phenomenon not responding to sildenafil.
Microvasc Res, 69 (2005), pp. 178-179
http://dx.doi.org/10.1016/j.mvr.2005.03.001 | Medline
[80.]
M.D. Mayes.
Endothelin and endothelin receptor antagonists in systemic
rheumatic disease.
Arthritis Rheum, 48 (2003), pp. 1190-1199
http://dx.doi.org/10.1002/art.10895 | Medline
[81.]
M. Ramos-Casals, P. Brito-Zeron, N. Nardi, G. Claver, G. Risco, F.D.
Parraga, et al.
Successful treatment of severe Raynaud’s phenomenon with
bosentan in four patients with systemic sclerosis.
Rheumatology (Oxford), 43 (2004), pp. 1454-1456
[82.]
J.H. Korn, M. Mayes, M. Matucci-Cerinic, M. Rainisio, J. Pope, E.
Hachulla, RAPIDS-1 Study Group, et al.
Digital ulcers in systemic sclerosis: Prevention by treatment with
bosentan, an oral endothelin receptor antagonist.
Arthritis Rheum, 50 (2004), pp. 3985-3993
http://dx.doi.org/10.1002/art.20676 | Medline
[83.]
B. Coleiro, S.E. Marshall, C.P. Denton, K. Howell, A. Blann, K.I.
Welsh, et al.
Treatment of Raynaud’s phenomenon with the selective serotonin
reuptake inhibitor fluoxetine.
Rheumatology (Oxford), 40 (2001), pp. 1038-1043
[84.]
J. Pope, D. Fenlon, A. Thompson, B. Shea, D. Furst, G. Wells, et al.
Ketanserin for Raynaud’s phenomenon in progressive systemic
sclerosis.
Cochrane Database Sys Rev, 1 (2005),
[85.]
C.B. Bunker, C. Reavley, D. O’Shaughnessy, P.M. Dowd.
Calcitonin generelated peptide in treatment of severe peripheral
vascular insufficiency in Raynaud’s phenomenon.
Lancet, 342 (1993), pp. 80-82
Medline
[86.]
V.L. Beckett, D.L. Conn, V. Fuster, P.J. Osmundson, C.G. Strong,
E.Y. Chao, et al.
Trial of platelet-inhibiting drug in scleroderma. Double-blind
study with dipyridamole and aspirin.
Arthritis Rheum, 27 (1984), pp. 1137-1143
Medline
[87.]
J. Van der Meer, A.A. Wouda, C.G. Kallenberg, H. Wesseling.
A doubleblind controlled trial of low dose acetylsalicylic acid and
dipyridamole in the treatment of Raynaud’s phenomenon.
Vasa Suppl, 18 (1987), pp. 71-75
Medline
[88.]
C.P. Denton, K. Howell, R.J. Stratton, C.M. Black.
Long-term low molecular weight heparin therapy for severe
Raynaud’s phenomenon: a pilot study.
Clin Exp Rheumatol, 18 (2000), pp. 499-502
Medline
[89.]
J.J. Belch, M. Ho.
Pharmacotherapy of Raynaud’s phenomenon.
Drugs, 52 (1996), pp. 682-695
Medline
[90.]
S. Rajagopalan, D. Pfenninger, E. Somers, C. Kehrer, A. Chakrabarti,
D. Mukherjee, et al.
Effects of cilostazol in patients with Raynaud’s syndrome.
Am J Cardiol, 92 (2003), pp. 1310-1315
Medline
[91.]
A.L. Herrick, M. Matucci Cerinic.
The emerging problem of oxidative stress and the role of
antioxidants in systemic sclerosis.
Clin Exp Rheumatol, 19 (2001), pp. 4-8
Medline
[92.]
A.L. Herrick.
Treatment of Raynaud’s phenomenon: new insights and
developments.
Curr Rheumatol Rep, 5 (2003), pp. 168-174
Medline
[93.]
C.P. Denton, T.D. Bunce, M.B. Darado, Z. Roberts, H. Wilson, K.
Howell, et al.
Probucol improves symptoms and reduces lipoprotein oxidation
susceptibility in patients with Raynaud’s phenomenon.
Rheumatology (Oxford), 38 (1999), pp. 309-315
[94.]
A.L. Herrick, S. Hollis, D. Schofield, F. Rieley, A. Blann, K.
Griffin, et al.
A double-blind placebo-controlled trial of antioxidant therapy in
limited cutaneous systemic sclerosis.
Clin Exp Rheumatol, 18 (2000), pp. 349-356
Medline
[95.]
M.E. Mavrikakis, J.P. Lekakis, C.M. Papamichael, K.S.
Stamatelopoulos, C.h.C. Kostopoulos, S.F. Stamatelopoulos.
Ascorbic acid does not improve endothelium-dependent flow-
mediated dilatation of the brachial artery in patients with
Raynaud’s phenomenon secondary to systemic sclerosis.
Int J Vitam Nutr Res, 73 (2003), pp. 3-7
http://dx.doi.org/10.1024/0300-9831.73.1.3 | Medline
[96.]
J.P. Johnson, C. Obasi, M.S. Hahn, P. Glatleider.
Endoscopic thoracic sympathectomy.
J Neurosurg Spine, 91 (1999), pp. 90-97
[97.]
J.C. De Trafford, K. Lafferty, C.E. Potter, V.C. Roberts, L.T. Cotton.
An epidemiological survey of Raynaud’s phenomenon.
Eur J Vasc Surg, 2 (1988), pp. 167-170
Medline
[98.]
A.E. Flatt.
Digital artery sympathectomy.
J Hand Surg, 5 (1980), pp. 550-556
[99.]
M.M. Tomaino, R.J. Goitz, T.A. Medsger.
Surgery for ischemic pain and Raynaud’s phenomenon in
scleroderma: a description of treatment protocol and evaluation
of results.
Microsurgery, 21 (2001), pp. 75-79
Medline